Market noise is relentless. Financial headlines scream about the same handful of stocks while important opportunities—the kind that can meaningfully impact your portfolio—often fly completely under the radar.
That’s exactly why we publish this watchlist each week.
This week reveals a fundamental reshuffling of energy infrastructure driven by artificial intelligence data center demand. Nuclear power provides 47% of the nation’s zero-emissions electricity and is experiencing renewed government support with $17.5 billion in loan commitments to finance construction of new reactors. Simultaneously, hydrogen fuel cells are entering mainstream deployment as data centers seek alternative power solutions, with major technology companies and energy developers locking in supply agreements. Meanwhile, escalating Middle East tensions remind investors why defensive positioning through Dividend Kings remains essential regardless of economic direction.
The energy sector is bifurcating: traditional solutions gaining renewed credibility alongside emerging technologies, both powering the infrastructure AI demands. And dividend aristocrats continue their quiet wealth compounding through every market cycle. These aren’t competing narratives—they’re complementary opportunities for different portfolio strategies.
While most investors are distracted by geopolitical anxiety and technology volatility, we’re identifying companies at genuine inflection points where valuations, catalysts, and fundamentals align.
Each week, we spotlight three stocks that merit your attention. We focus on opportunities where timing, valuation, and catalysts align to create potentially favorable entry points.
Our rigorous analysis goes beyond surface-level metrics to identify opportunities that most retail investors don’t have time to uncover. Each pick comes with clear reasoning, specific triggers to watch for, and a compelling risk-adjusted profile designed to help you make more informed investment decisions.
Here’s what we’re watching this week:
Cameco (CCJ) — Uranium Producer Positioned for Nuclear Renaissance and Data Center Power Surge
Cameco represents an exceptional opportunity as the world’s largest uranium producer benefits from dual tailwinds: government commitments to triple nuclear energy capacity by 2050 and surging demand from artificial intelligence data centers requiring baseload power. Trading around $86 per share with a $37 billion market capitalization, down 36% from its 52-week high despite fundamentals strengthening, the company offers entry point into nuclear-driven infrastructure buildout backed by high-grade North American mines and a 49% stake in Westinghouse reactor technology.
The investment thesis centers on Cameco’s positioning as the critical link between nuclear energy expansion and AI infrastructure demands. Nuclear power provides 47% of the nation’s zero-emissions electricity—more than wind and solar combined—while offering stable baseload power that enables 24/7 operations regardless of weather conditions. As data centers proliferate across the globe to support AI applications, companies are turning to nuclear energy to meet long-term power requirements, creating multi-decade visibility for uranium demand.
Cameco owns controlling stakes in McArthur River and Cigar Lake mines in Canada’s Athabasca Basin—among the world’s highest-grade uranium operations with lower operating costs and robust competitive advantages. The company has committed to delivering 28 million pounds of uranium annually over the next five years while maintaining inventory discipline to prevent market flooding. The March 2026 agreement with India’s Department of Atomic Energy to supply 22 million pounds of uranium ore concentrate through 2035 validates long-term demand and locks in revenue visibility.
The Westinghouse stake amplifies upside as the reactor technology company benefits from nuclear infrastructure buildout. The U.S. Department of Energy conditionally committed $17.5 billion in loan facilities to support U.S. nuclear reactors, financing equipment for construction of at least 10 Westinghouse AP1000 reactors. Cameco benefits from both uranium fuel supply for these new facilities and equity participation in Westinghouse’s technology deployment and servicing revenues.
The valuation at 36% below 52-week highs despite strengthening fundamentals and locked-in supply contracts appears excessive. The stock has experienced significant volatility as investors digest nuclear energy buildout news, but the near-term pullback creates entry opportunity for investors recognizing that nuclear expansion and AI data center power demands remain structurally intact regardless of short-term sentiment.
For energy investors seeking nuclear exposure, Cameco’s combination of high-grade North American uranium mines providing competitive cost advantage, 28 million pounds annual supply commitment through disciplined inventory management, $2.6 billion India supply agreement through 2035 locking in revenue, 49% Westinghouse stake benefiting from $17.5 billion DOE nuclear construction financing, dual tailwinds from government nuclear expansion and AI data center power demands, and 36% decline from 52-week highs creating entry opportunity creates compelling risk-adjusted opportunity in uranium producer positioned for multi-decade nuclear renaissance driven by both climate policy and artificial intelligence infrastructure requirements.
Bloom Energy (BE) — Hydrogen Fuel Cell Leader Entering Mainstream Data Center Power Deployment
Bloom Energy presents an exceptional opportunity as hydrogen fuel cells transition from niche technology to mainstream power solution for artificial intelligence data centers, with major technology and infrastructure companies locking in supply agreements validating the inflection point. Trading around $214 per share with a $61 billion market capitalization after declining 40% from late-June peaks, the company offers entry into emerging clean energy infrastructure that the market is just beginning to price correctly.
The investment thesis centers on Bloom Energy’s positioning at the intersection of three powerful trends: exploding data center power demands, hydrogen fuel cell entering mainstream deployment, and major infrastructure companies committing capital to fuel cell solutions. The evidence is stacking up rapidly as deals proliferate between fuel cell makers and electricity-hungry data center operators. ECL inked a contract to deploy 300 megawatts of hydrogen fuel cells from Sweden’s PowerCell, Siemens agreed to co-develop distributed energy solutions for data centers with FuelCell Energy, and Brookfield announced plans to quintuple its initial $5 billion purchase of power infrastructure from Bloom Energy.
Technology giant Oracle’s decision to more than double its power needs from Bloom from 1.2 gigawatts to 2.8 gigawatts demonstrates that major technology leaders are betting capital on Bloom’s fuel cell solutions for powering AI infrastructure. These aren’t pilot programs or tests—they’re production-scale commitments from companies with extraordinary resources and sophisticated capital discipline. When companies like Oracle and Brookfield deploy billions in infrastructure, the technology has entered mainstream territory.
Bloom Energy’s solid-oxide fuel cells offer unique advantages versus competitors by utilizing natural gas, biogas, or hydrogen, providing flexibility as the energy infrastructure evolves. This versatility creates competitive moat as data centers can deploy Bloom solutions today using natural gas while transitioning to hydrogen as availability improves, rather than requiring complete infrastructure replacement. The Mordor Intelligence forecast of 37% annual fuel cell market growth through 2031 validates the secular tailwind.
The company has achieved profitability while still capturing early growth from fuel cell market inflection. The near-term stock volatility from late-June peaks appears driven by profit-taking rather than fundamental deterioration, as the underlying business momentum—evidenced by major customer commitments—continues accelerating. The 40% pullback creates entry opportunity for investors recognizing that hydrogen fuel cell deployment is reaching critical mass in 2026.
For energy and technology infrastructure investors seeking clean power exposure, Bloom Energy’s combination of major customer commitments from Oracle, Brookfield, and technology companies deploying billions in fuel cell infrastructure, Mordor Intelligence forecasting 37% annual fuel cell market growth through 2031, solid-oxide fuel cell technology offering versatility across fuel sources, already profitable operations with expanding margins expected, hydrogen fuel industry entering mainstream deployment recognizing critical mass, and 40% decline from late-June peaks creating entry opportunity creates compelling risk-adjusted opportunity in fuel cell leader positioned to capitalize on hydrogen entering mainstream for AI data center power solutions.
AbbVie (ABBV) — Pharmaceutical Dividend King With Defensive Positioning Through Uncertainty
AbbVie represents a foundational opportunity as the pharmaceutical Dividend King with 54 consecutive years of dividend increases provides defensive positioning through economic uncertainty and geopolitical tensions while maintaining growth catalysts from promising pipeline developments. Trading around $254 per share with a $450 billion market capitalization offering 2.68% dividend yield—substantially above S&P 500 average of 1.1%—the company exemplifies the defensive characteristics essential during periods of heightened geopolitical risk.
The investment thesis centers on AbbVie’s recession-resistant business model combined with meaningful growth catalysts. The pharmaceutical leader boasts a deep portfolio of medicines across multiple therapeutic areas, with immunology representing the growth engine through Skyrizi and Rinvoq performing even better than management anticipated. These two growth pillars should maintain sales growth for extended periods while the company develops new growth drivers to offset eventual patent expirations.
The anti-obesity market represents significant white space where AbbVie’s investigational weight-loss medicine ABBV-295 could prove highly differentiated. The candidate can be administered monthly versus weekly for current category leaders, addressing patient preference for less frequent dosing. Early-stage studies demonstrated promise, positioning AbbVie advantageously in a rapidly growing market expected to expand significantly as obesity prevalence increases and treatment options proliferate.
The recent acquisition of Apogee Therapeutics and its immunology candidate zumilokibart for eczema demonstrates management’s strategic capital deployment toward higher-growth therapeutic areas. The deep pipeline extends beyond these acquisitions, with significant clinical and regulatory progress expected over coming years. The combination of in-house development and acquisitions creates multiple pathways to offset patent cliff risks.
The 54-year dividend increase streak represents extraordinary commitment to shareholder returns through multiple recessions, geopolitical crises, and market disruptions. The products AbbVie offers are always in high demand regardless of economic conditions, ensuring reliable cash flows supporting dividend sustainability and growth. The forward dividend yield of 2.8% provides meaningful income while the company simultaneously invests in pipeline development and strategic acquisitions.
For defensive income investors seeking pharmaceutical exposure through geopolitical uncertainty, AbbVie’s combination of 54-year dividend increase streak representing quarter-century of uninterrupted commitment, immunology growth pillars Skyrizi and Rinvoq performing above expectations, anti-obesity ABBV-295 candidate offering monthly dosing advantage in rapidly growing market, Apogee acquisition bringing zumilokibart eczema therapy strengthening immunology position, deep pipeline supporting long-term growth, 2.68% dividend yield exceeding S&P 500 average, and products always in high demand regardless of economic conditions creates compelling risk-adjusted opportunity for defensive positioning while maintaining growth exposure through pharmaceutical innovation and market expansion.
